Instruction Manual

Bordetella FHA IgG ELISA

Enzyme immunoassay based on microtiter plate for the detection and quantitative determination of human IgG antibodies against Bordetella pertussis FHA in serum and plasma

Cat. No.: ILE-BPT07
Storage: 2-8°C
For in-vitro diagnostic use only

December 2014

IMMUNOLAB GmbH, Otto-Hahn-Str. 16, D-34123 Kassel
Tel: +561 491742-0, Fax: +561 491742-20, E-Mail: info@immunolab.de
## Contents

1. Intended Use 3  
2. General Information 3  
3. Principle of the Tests 3  
4. Limitations, Precautions and General Comments 4  
5. Reagents Provided 4  
6. Materials Required but not Provided 5  
7. Specimen Collection and Handling 6  
8. Assay Procedure 6  
9. Evaluation 7  
10. Assay Characteristics 8  
11. References 8  

### Symbole und Übersetzungen / Symbols and Translations

<table>
<thead>
<tr>
<th>Symbol</th>
<th>English</th>
<th>French</th>
<th>German</th>
<th>Italian</th>
<th>Spanish</th>
<th>Greek</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAL</td>
<td>Calibrator</td>
<td>Calibrateur</td>
<td>Kalibrator</td>
<td>Calibratore</td>
<td>Calibrador</td>
<td>Πρότυπο</td>
</tr>
<tr>
<td>CONJ</td>
<td>Conjugate</td>
<td>Conjugué</td>
<td>Konjugat</td>
<td>Coniugato</td>
<td>Conjugado</td>
<td>Διάλυμα</td>
</tr>
<tr>
<td>CONC</td>
<td>Concentrate (&lt;n&gt;-fold)</td>
<td>Concentré (&lt;n&gt; fois)</td>
<td>Konzentrat (&lt;n&gt;-fach)</td>
<td>Concentrato (&lt;n&gt;-volte)</td>
<td>Concentrado (&lt;n&gt;-veces)</td>
<td>Συμπύκνωση (&lt;n&gt; φορές)</td>
</tr>
<tr>
<td>SAMP DIL</td>
<td>Sample Diluent</td>
<td>Diluant échantillon</td>
<td>Proben-verdünnner</td>
<td>Diluente del campione</td>
<td>Diluyente de muestra</td>
<td>Διάλυμα Αραίωσης</td>
</tr>
<tr>
<td>STOP</td>
<td>Stop Solution</td>
<td>Solution d'arrêt</td>
<td>Stopp-Lösung</td>
<td>Soluzione d'arresto</td>
<td>Solución de parada</td>
<td>Διάλυμα Αναστολής</td>
</tr>
<tr>
<td>SUBS</td>
<td>Substrate</td>
<td>Substrat</td>
<td>Substrat</td>
<td>Substrato</td>
<td>Sustrato</td>
<td>Διάλυμα Υποστρώματος</td>
</tr>
<tr>
<td>MT PLATE</td>
<td>Microtiter plate</td>
<td>Microplaque</td>
<td>Mikrotiterplatte</td>
<td>Piastre</td>
<td>Placa microtiter</td>
<td>Μικρότιπλακα</td>
</tr>
<tr>
<td>WASH BUF</td>
<td>Wash buffer</td>
<td>Tampon de lavage</td>
<td>Waschpuffer</td>
<td>Soluzione di lavaggio</td>
<td>Tampón de lavado</td>
<td>Πλυστικό Διάλυμα</td>
</tr>
</tbody>
</table>
1. Intended Use

The IMMUNOLAB Bordetella FHA IgG Antibody ELISA Test Kit has been designed for the detection and the quantitative determination of specific IgG antibodies against Bordetella FHA in serum and plasma. Further applications in other body fluids are possible and can be requested from the Technical Service of IMMUNOLAB.

Laboratory results can never be the only base of a medical report. The patient history and further tests have additionally to be taken into account.

2. General Information

Whooping cough is a disease of the respiratory tracts which is caused by Bordetella pertussis bacteria. It is transmitted by airborne infection. The gramnegative Coccobacillus produces a series of biologically active molecules. The different compounds appear either during the pathogenesis or during the process of immunization against pertussis and show different effects. A characterisation has been made for the pertussis toxin (pt), the filamentery haemagglutinine (fha) and different lipopolysaccharides (lps).

Pertussis shows a high rate of transmission (rates of infection of over 90 % have been found for non-vaccinated household members) and can cause severe diseases, especially for very young children. In older children and adults the disease may manifests itself by unspecific brochitic symptoms or inflammation of the upper respiratory tract. School children which are not totally immune may develop whooping cough and infect younger children easily. This applies also to infected adults. The development of antibodies towards Bordetella pertussis during a pertussis disease reveals itself by a relatively long serologically negative initial phase, followed by a rapid increase of at first IgA und IgM antibodies and lastly IgG. Of 259 sera derived from children and adults with suspected whooping cough 142 were confirmed positive by an ELISA. Due to the broad application of Bordetella vaccines a significant reduction of the incidence and fatal casualties caused by whooping cough were achieved. A precise method for the quantification of the antibody concentration against Bordetella pertussis in serum is required to assess the success of a pertussis vaccination, diagnose an infection and detect diaplancental transfer of maternal antibodies.

FHA is a 220 kDa sized surface antigen of Bordetella pertussis and Bordetella parapertussis which agglutinates erythrocytes in vitro. It is a component of numerous vaccines. For this reason a simple, fast, sensitive and according to an international reference preparation calibrated ELISA test kit for the detection of Bordetella FHA IgG antibodies was developed.

3. Principle of the Tests

The IMMUNOLAB Bordetella FHA IgG antibody test kit is based on the principle of the enzyme immunoassay (EIA). Bordetella FHA antigen is bound on the surface of the microtiter strips. Diluted patient serum or ready-to-use standards are pipetted into the wells of the microtiter plate. A binding between the IgG antibodies of the serum and the immobilized Bordetella FHA antigen takes place. After a one hour incubation at room temperature, the plate is rinsed with diluted wash solution, in order to remove unbound material. Then ready-to-use anti-human-IgG peroxidase conjugate is added and incubated for 30 minutes. After a further washing step, the substrate (TMB) solution is pipetted and incubated for 20 minutes, inducing the development of a blue dye in the wells. The color development is terminated by the addition of a stop solution, which changes the color from blue to yellow. The resulting dye is measured spectrophotometrically at the wavelength of 450 nm. The concentration of the IgG antibodies is directly proportional to the intensity of the color.
4. Limitations, Precautions and General Comments

- Only for in-vitro use! Do not ingest or swallow! The usual laboratory safety precautions as well as the prohibition of eating, drinking and smoking in the lab have to be followed.
- All sera and plasma or buffers based upon, have been tested respective to HBsAg, HIV and HCV with recognized methods and were found negative. Nevertheless precautions like the use of latex gloves have to be taken.
- Serum and reagent spills have to be wiped off with a disinfecting solution (e.g. sodium hypochlorite, 5%) and have to be disposed of properly.
- All reagents have to be brought to room temperature (18 to 25 °C) before performing the test.
- Before pipetting all reagents should be mixed thoroughly by gentle tilting or swinging. Vigorous shaking with formation of foam should be avoided.
- It is important to pipet with constant intervals, so that all the wells of the microtiter plate have the same conditions.
- When removing reagents out of the bottles, care has to be taken that the stoppers are not contaminated. Further a possible mix-up has to be avoided. The content of the bottles is usually sensitive to oxidation, so that they should be opened only for a short time.
- In order to avoid a carry-over or a cross-contamination, separate disposable pipet tips have to be used.
- All reagents have to be used within the expiry period.
- In accordance with a Good Laboratory Practice (GLP) or following ISO9001 all laboratory devices employed should be regularly checked regarding the accuracy and precision. This refers amongst others to microliter pipets and washing or reading (ELISA-Reader) instrumentation.
- The contact of certain reagents, above all the stopping solution and the substrate with skin, eye and mucosa has to be avoided, because possible irritations and acid burns could arise, and there exists a danger of intoxication.

5. Reagents Provided

<table>
<thead>
<tr>
<th>Components</th>
<th>Volume / Qty.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bordetella FHA antigen coated microtiter strips</td>
<td>12</td>
</tr>
<tr>
<td>Standards with 0, 25, 100 and 250 IU/mL</td>
<td>2 mL</td>
</tr>
<tr>
<td>Enzyme Conjugate</td>
<td>15 mL</td>
</tr>
<tr>
<td>Substrate</td>
<td>15 mL</td>
</tr>
<tr>
<td>Stop Solution</td>
<td>15 mL</td>
</tr>
<tr>
<td>Sample Diluent</td>
<td>60 mL</td>
</tr>
<tr>
<td>Washing Buffer (10×)</td>
<td>60 mL</td>
</tr>
<tr>
<td>Plastic foils</td>
<td>2</td>
</tr>
<tr>
<td>Plastic bag</td>
<td>1</td>
</tr>
</tbody>
</table>

**Storage and Stability** (refer to the expiry date on the outer box label)
Store kit components at 2-8°C. After use, the plate should be resealed, the bottle caps replaced and tightened and the kit stored at 2-8°C. The opened kit should be used within three months.
Universal Reagents
Washing buffer, substrate and stop solution are identical for all infectious disease test kits from IMMUNOLAB with Peroxidase as detecting enzyme and may be interchanged between products and lots. All other reagents are assigned to a special kit lot and must not be mixed.

5.1. Mikrotiter Strips
12 strips with 8 breakable wells each, coated with Bordetella FHA antigen (strain Tohama). Ready-to-use.

5.2. Standards
4 x 2 mL, human serum diluted with PBS, with 0, 25, 100 and 250 IU/mL of IgG antibodies against Bordetella FHA. Addition of 0.01 % methylisothiazolone and 0.01 % bromonitrodiioxane. The ready-to-use Bordetella FHA standards are calibrated against the WHO reference preparation 06/140.

5.3. Enzyme Conjugate
15 mL, anti-human-IgG-HRP (rabbit), in protein-containing buffer solution. Addition of 0.01 % methylisothiazolone and 0.01 % bromonitrodiioxane and 5 mg/L Proclin™. Ready-to-use.

5.4. Substrate
15 mL, TMB (tetramethylbenzidine). Ready-to-use.

5.5. Stop Solution
15 mL, 0.5 M sulfuric acid. Ready-to-use.

5.6. Sample Diluent
60 mL, PBS/BSA buffer. Addition of 0.095 % sodium azide. Ready-to-use.

5.7. Washing Buffer
60 mL, PBS + Tween 20, 10x concentrate. Final concentration: dilute 1+9 with deionized water. If during the cold storage crystals precipitate, the concentrate should be warmed up at 37°C for 15 minutes.

5.8. Plastic Foils
2 pieces to cover the microtiter strips during the incubation.

5.9. Plastic Bag
Resealable, for the dry storage of non-used strips.

6. Materials Required but not Provided
- 5 µL-, 100 µL- and 500 µL micro- and multichannel pipets
- Microtiter Plate Reader (450 nm)
- Microtiter Plate Washer
- Reagent tubes for the serum dilution
- Deionized water
7. Specimen Collection and Handling

Principally serum or plasma (EDTA, heparin) can be used for the determination. Serum is separated from the blood, which is aseptically drawn by venipuncture, after clotting and centrifugation. The serum or plasma samples can be stored refrigerated (2-8°C) for up to 7 days. For a longer storage they should be kept at -20°C. The samples should not be frozen and thawed repeatedly. Lipemic, hemolytic or bacterially contaminated samples can cause false positive or false negative results.

For the performance of the test the samples (not the standards) have to be diluted 1:101 with ready-to-use sample diluent (e.g. 5 µL serum + 500 µL sample diluent).

8. Assay Procedure

8.1. Preparation of Reagents

Washing Solution: dilute before use 1+9 with deionized water. If during the cold storage crystals precipitate, the concentrate should be warmed up at 37°C for 15 minutes.

- Strict adherence to the protocol is advised for reliable performance. Any changes or modifications are the responsibility of the user.
- All reagents and samples must be brought to room temperature before use, but should not be left at this temperature longer than necessary.
- A standard curve should be established with each assay.
- Return the unused microtiter strips to the plastic bag and store them dry at 2-8°C.

8.2. Assay Steps

1. Prepare a sufficient amount of microtiter wells for the standards, controls and samples as well as for a substrate blank.
2. Pipet 100 µL each of the diluted (1:101) samples and the ready-to-use standards and controls respectively into the wells. Leave one well empty for the substrate blank.
3. Cover plate with the enclosed foil and incubate at room temperature for 60 minutes.
4. Empty the wells of the plate (dump or aspirate) and add 300 µL of diluted washing solution. This procedure is repeated totally three times. Rests of the washing buffer are afterwards removed by gentle tapping of the microtiter plate on a tissue cloth.
5. Pipet 100 µL each of ready-to-use conjugate into the wells. Leave one well empty for the substrate blank.
6. Cover plate with the enclosed foil and incubate at room temperature for 30 minutes.
7. Empty the wells of the plate (dump or aspirate) and add 300 µL of diluted washing solution. This procedure is repeated totally three times. Rests of the washing buffer are afterwards removed by gentle tapping of the microtiter plate on a tissue cloth.
8. Pipet 100 µL each of the ready-to-use substrate into the wells. This time also the substrate blank is pipetted.
9. Cover plate with the enclosed foil and incubate at room temperature for 20 minutes in the dark (e.g. drawer).
10. To terminate the substrate reaction, pipet 100 µL each of the ready-to-use stop solution into the wells. Pipet also the substrate blank.
11. After thorough mixing and wiping the bottom of the plate, perform the reading of the absorption at 450 nm (optionally reference wavelength of 620 nm). The color is stable for at least 60 minutes.
9. Evaluation

Example

<table>
<thead>
<tr>
<th>Substrate Blank</th>
<th>OD Value</th>
<th>Corrected OD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>0.020</td>
<td></td>
</tr>
<tr>
<td>Standard 1 (0 IU/mL)</td>
<td>0.030</td>
<td>0.010</td>
</tr>
<tr>
<td>Standard 1 (25 IU/mL)</td>
<td>0.507</td>
<td>0.487</td>
</tr>
<tr>
<td>Standard 1 (100 IU/mL)</td>
<td>1.531</td>
<td>1.511</td>
</tr>
<tr>
<td>Standard 1 (250 IU/mL)</td>
<td>2.492</td>
<td>2.472</td>
</tr>
</tbody>
</table>

The above table contains only an example, which was achieved under arbitrary temperature and environmental conditions. The described data constitute consequently no reference values which have to be found in other laboratories in the same way.

9.1. Qualitative Evaluation

The calculated absorptions for the patient sera, as mentioned above, are compared with the value for the cut-off standard (=25 IU/mL). If the value of the sample is higher, there is a positive result. For a value below the cut-off standard, there is a negative result. It seems reasonable to define a range of +/-20 % around the value of the cut-off as a grey zone. In such a case the repetition of the test with the same serum or with a new sample of the same patient, taken after 2-4 weeks, is recommended. Both samples should be measured in parallel in the same run.

The absorbance value of Standard 4 needs to be at least twice as high compared to Standard 2.

9.2. Quantitative Evaluation

The ready-to-use standards and controls of the Bordetella FHA IgG antibody kit are calibrated using the WHO reference preparation 06/140. As such they are expressed in International Units (IU). This results in an exact and reproducible quantitative evaluation. Consequently for a given patient follow-up controls become possible. The values for controls and standards in units are printed on the labels of the vials.

For a quantitative evaluation the absorptions of the standards and controls are graphically drawn point-to-point against their concentrations. From the resulting reference curve the concentration values for each patient sample can then be extracted in relation to their absorptions. It is also possible to use automatic computer programs. As curve fit point-to-point has to be chosen.

Standard 2 with its concentration of 25 IU/mL serves as cut-off standard. Analogous to the qualitative evaluation a range of +/-20% around the cut-off is defined as a grey zone. Thus results between 20 and 30 IU/mL are reported as borderline.
10. Assay Characteristics

<table>
<thead>
<tr>
<th>Bordetella FHA ELISA</th>
<th>IgG</th>
<th>IgA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intra-Assay-Precision</td>
<td>4.8 – 7.2 %</td>
<td>6.0 – 12.6 %</td>
</tr>
<tr>
<td>Inter-Assay-Precision</td>
<td>6.2 – 17.0 %</td>
<td>8.1 – 17.1 %</td>
</tr>
<tr>
<td>Inter-Lot-Precision</td>
<td>2.6 23.1 %</td>
<td>7.2 – 11.2 %</td>
</tr>
<tr>
<td>Analytical Sensitivity</td>
<td>0.5 IU/mL</td>
<td>0.5 IU/mL</td>
</tr>
<tr>
<td>Recovery</td>
<td>102 – 108 %</td>
<td>86 – 113 %</td>
</tr>
<tr>
<td>Linearity</td>
<td>80 – 134 %</td>
<td>71 – 155 %</td>
</tr>
<tr>
<td>Cross-Reactivity</td>
<td>No cross-reactivity to Adenovirus, Parainfluenza 1/2/3 and RSV.</td>
<td>No cross-reactivity to Helicobacter, Transglutaminase and Mycoplasma.</td>
</tr>
<tr>
<td>Interferences</td>
<td>No interferences to bilirubin up to 0.3 mg/mL, hemoglobin up to 8.0 mg/mL and triglycerides up to 5.0 mg/mL</td>
<td></td>
</tr>
<tr>
<td>Clinical Specificity</td>
<td>86 %</td>
<td>100 %</td>
</tr>
<tr>
<td>Clinical Sensitivity</td>
<td>100 %</td>
<td>100 %</td>
</tr>
<tr>
<td>Measuring Range</td>
<td>25 – 250 IU/mL</td>
<td>10 – 50 IU/mL</td>
</tr>
</tbody>
</table>

11. References